In individuals with mild cognitive impairment (MCI) or dementia, evidence of cerebral amyloid and tau accumulation accompanying neurodegeneration is necessary to confirm the diagnosis of Alzheimer’s disease (AD)1. The gene discussed is MAPT; the disease is Cognitive impairment.